Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/591ef5e54f8e4c339a69acbcf691130d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:591ef5e54f8e4c339a69acbcf691130d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:591ef5e54f8e4c339a69acbcf691130d2021-11-14T09:00:14ZInsulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)2072-03512072-037810.14341/2072-0351-6022https://doaj.org/article/591ef5e54f8e4c339a69acbcf691130d2010-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6022https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(mostly NPX insulin). The incidence of breast cancer was equal (0.1%) in both groups (4 and 6 cases respectively). These data indicate thatthe use of insuline glargine does not increase the risk of malignancy, e.g. breast cancer.Marina Vladimirovna ShestakovaIrina Vladimirovna GlinkinaEndocrinology Research Centrearticlediabetes mellitusinsulin glarginemalignant neoplasmsbreast cancerNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 1, Pp 88-90 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
diabetes mellitus insulin glargine malignant neoplasms breast cancer Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
diabetes mellitus insulin glargine malignant neoplasms breast cancer Nutritional diseases. Deficiency diseases RC620-627 Marina Vladimirovna Shestakova Irina Vladimirovna Glinkina Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| description |
Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(mostly NPX insulin). The incidence of breast cancer was equal (0.1%) in both groups (4 and 6 cases respectively). These data indicate thatthe use of insuline glargine does not increase the risk of malignancy, e.g. breast cancer. |
| format |
article |
| author |
Marina Vladimirovna Shestakova Irina Vladimirovna Glinkina |
| author_facet |
Marina Vladimirovna Shestakova Irina Vladimirovna Glinkina |
| author_sort |
Marina Vladimirovna Shestakova |
| title |
Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_short |
Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_full |
Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_fullStr |
Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_full_unstemmed |
Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506) |
| title_sort |
insulin glargine does not increase the risk of malignancy.synopsis of the article ?combined randomised controlled trial experience of malignancies in studies using insulin glargine?byhome p.d. & lagarenne p. (diabetologia 2009, vol. 52 (12): 2499-2506) |
| publisher |
Endocrinology Research Centre |
| publishDate |
2010 |
| url |
https://doaj.org/article/591ef5e54f8e4c339a69acbcf691130d |
| work_keys_str_mv |
AT marinavladimirovnashestakova insulinglarginedoesnotincreasetheriskofmalignancysynopsisofthearticlecombinedrandomisedcontrolledtrialexperienceofmalignanciesinstudiesusinginsulinglarginebyhomepdamplagarennepdiabetologia2009vol521224992506 AT irinavladimirovnaglinkina insulinglarginedoesnotincreasetheriskofmalignancysynopsisofthearticlecombinedrandomisedcontrolledtrialexperienceofmalignanciesinstudiesusinginsulinglarginebyhomepdamplagarennepdiabetologia2009vol521224992506 |
| _version_ |
1718429649923473408 |